Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

Antonio M. Almeida; Thomas Prebet; Raphael Itzykson; Fernando Ramos; Haifa Al-Ali; Jamile Shammo; Ricardo Pinto; Luca Maurillo; Jaime Wetzel; Pellegrino Musto; Arjan A. Van De Loosdrecht; Maria Joao Costa; Susana Esteves; Sonja Burgstaller; Reinhard Stauder; Eva M. Autzinger; Alois Lang; Peter Krippl; Dietmar Geissler; Jose Francisco Falantes; Carmen Pedro; Joan Bargay; Guillermo Deben; Ana Garrido; Santiago Bonanad; Maria Diez-Campelo; Sylvain Thepot; Lionel Ades; Wolfgang R. Sperr; Peter Valent; Pierre Fenaux; Mikkael A. Sekeres; Richard Greil; Lisa Pleyer

doi:https://doi.org/10.3390/ijms18040837

Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

Antonio M. Almeida, Thomas Prebet, Raphael Itzykson, Fernando Ramos, Haifa Al-Ali, Jamile Shammo, Ricardo Pinto, Luca Maurillo, Jaime Wetzel, Pellegrino Musto, Arjan A. Van De Loosdrecht, Maria Joao Costa, Susana Esteves, Sonja Burgstaller, Reinhard Stauder, Eva M. Autzinger, Alois Lang, Peter Krippl, Dietmar Geissler, Jose Francisco FalantesCarmen Pedro, Joan Bargay, Guillermo Deben, Ana Garrido, Santiago Bonanad, Maria Diez-Campelo, Sylvain Thepot, Lionel Ades, Wolfgang R. Sperr, Peter Valent, Pierre Fenaux, Mikkael A. Sekeres, Richard Greil, Lisa Pleyer

Research output: Contribution to journal › Article › Academic › peer-review

20 Citations (Scopus)

Abstract

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

Original language	English
Article number	837
Journal	International journal of molecular sciences
Volume	18
Issue number	4
DOIs	https://doi.org/10.3390/ijms18040837
Publication status	Published - 14 Apr 2017

Keywords

Acute erythroleukemia
Azacitidine
Decitabine

Access to Document

https://doi.org/10.3390/ijms18040837

Cite this

Almeida, A. M., Prebet, T., Itzykson, R., Ramos, F., Al-Ali, H., Shammo, J., Pinto, R., Maurillo, L., Wetzel, J., Musto, P., Van De Loosdrecht, A. A., Costa, M. J., Esteves, S., Burgstaller, S., Stauder, R., Autzinger, E. M., Lang, A., Krippl, P., Geissler, D., ... Pleyer, L. (2017). Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study. International journal of molecular sciences, 18(4), Article 837. https://doi.org/10.3390/ijms18040837

@article{39ce37b801094cff9458a49d893d3a42,

title = "Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study",

abstract = "Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.",

keywords = "Acute erythroleukemia, Azacitidine, Decitabine",

author = "Almeida, {Antonio M.} and Thomas Prebet and Raphael Itzykson and Fernando Ramos and Haifa Al-Ali and Jamile Shammo and Ricardo Pinto and Luca Maurillo and Jaime Wetzel and Pellegrino Musto and {Van De Loosdrecht}, {Arjan A.} and Costa, {Maria Joao} and Susana Esteves and Sonja Burgstaller and Reinhard Stauder and Autzinger, {Eva M.} and Alois Lang and Peter Krippl and Dietmar Geissler and Falantes, {Jose Francisco} and Carmen Pedro and Joan Bargay and Guillermo Deben and Ana Garrido and Santiago Bonanad and Maria Diez-Campelo and Sylvain Thepot and Lionel Ades and Sperr, {Wolfgang R.} and Peter Valent and Pierre Fenaux and Sekeres, {Mikkael A.} and Richard Greil and Lisa Pleyer",

year = "2017",

month = apr,

day = "14",

doi = "https://doi.org/10.3390/ijms18040837",

language = "English",

volume = "18",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

Almeida, AM, Prebet, T, Itzykson, R, Ramos, F, Al-Ali, H, Shammo, J, Pinto, R, Maurillo, L, Wetzel, J, Musto, P, Van De Loosdrecht, AA, Costa, MJ, Esteves, S, Burgstaller, S, Stauder, R, Autzinger, EM, Lang, A, Krippl, P, Geissler, D, Falantes, JF, Pedro, C, Bargay, J, Deben, G, Garrido, A, Bonanad, S, Diez-Campelo, M, Thepot, S, Ades, L, Sperr, WR, Valent, P, Fenaux, P, Sekeres, MA, Greil, R & Pleyer, L 2017, 'Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study', International journal of molecular sciences, vol. 18, no. 4, 837. https://doi.org/10.3390/ijms18040837

TY - JOUR

T1 - Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line

T2 - A retrospective multinational study

AU - Almeida, Antonio M.

AU - Prebet, Thomas

AU - Itzykson, Raphael

AU - Ramos, Fernando

AU - Al-Ali, Haifa

AU - Shammo, Jamile

AU - Pinto, Ricardo

AU - Maurillo, Luca

AU - Wetzel, Jaime

AU - Musto, Pellegrino

AU - Van De Loosdrecht, Arjan A.

AU - Costa, Maria Joao

AU - Esteves, Susana

AU - Burgstaller, Sonja

AU - Stauder, Reinhard

AU - Autzinger, Eva M.

AU - Lang, Alois

AU - Krippl, Peter

AU - Geissler, Dietmar

AU - Falantes, Jose Francisco

AU - Pedro, Carmen

AU - Bargay, Joan

AU - Deben, Guillermo

AU - Garrido, Ana

AU - Bonanad, Santiago

AU - Diez-Campelo, Maria

AU - Thepot, Sylvain

AU - Ades, Lionel

AU - Sperr, Wolfgang R.

AU - Valent, Peter

AU - Fenaux, Pierre

AU - Sekeres, Mikkael A.

AU - Greil, Richard

AU - Pleyer, Lisa

PY - 2017/4/14

Y1 - 2017/4/14

N2 - Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

AB - Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. Themedian survival ranges between 3-9months frominitial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

KW - Acute erythroleukemia

KW - Azacitidine

KW - Decitabine

UR - http://www.scopus.com/inward/record.url?scp=85018470782&partnerID=8YFLogxK

U2 - https://doi.org/10.3390/ijms18040837

DO - https://doi.org/10.3390/ijms18040837

M3 - Article

C2 - 28420120

SN - 1661-6596

VL - 18

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 4

M1 - 837

ER -

Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

Abstract

Keywords

Access to Document

Other files and links

Cite this